Novel chemotherapeutic agents for the treatment of brain cancer

Bibliography

• NEWTON HB: Primary brain tumors: Review of etiology, diagnosis and treatment. Am. Farm Phys. (1994) 49:787–797.
   PubMed Web of Science ®Google Scholar
• ••A thorough review.
   Google Scholar
• PRADOS MD, BERGER MS, WILSON CB: Primary central nervous system tumors: Advances in knowledge and treatment. Ca.. Cancer. J. Clin. (1998) 48:331–360.
   PubMed Web of Science ®Google Scholar
• ••A thorough review.
   Google Scholar
• NEWTON HB: Neurological complications of systemic cancer. Am. Fam. Phys. (1999) 59:878–886.
   PubMed Web of Science ®Google Scholar
• •Reviews the neurological complications of cancer, including MBT.
   Google Scholar
• WEN PY, LOEFFLER JS: Management of brain metastases. Oncology (1999) 13:941–961.
   PubMed Web of Science ®Google Scholar
• ••A thorough review.
   Google Scholar
• PECH IV, PETERSON K, CAIRNCROSS JG: Chemotherapy for brain tumors. Oncology (1998) 12:537–547.
   PubMed Web of Science ®Google Scholar
• ••A thorough review.
   Google Scholar
• NEWTON HB, TUROWSKI RC, STROUP TJ, MCCOY LK: Clinical presentation, diagnosis and pharmaco-therapy of patients with primary brain tumors. Ann. Pharmacother. (1999) 33:816–832.
   PubMed Web of Science ®Google Scholar
• ••A thorough review of PBT pharmacotherapy.
   Google Scholar
• LESSER GJ: Chemotherapy of cerebral metastases from solid tumors. Neurosurg. Clin. North Am. (1996) 7:527–536.
   PubMed Web of Science ®Google Scholar
• ••A thorough review.
   Google Scholar
• FINE HA, DEAR KBG, LOEFFLER JS, BLACK PM, CANELLOS GP: Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer (1993) 71:2585–2597.
   PubMed Web of Science ®Google Scholar
• ••Meta-analysis demonstrates survival advantage forchemotherapy.
   Google Scholar
• STEVENS MFG, NEWLANDS ES: From triazines and triazenes to temozolomide. Eur. J. Cancer (1993) 20A:1045–1047.
   Google Scholar
• •Reviews development of temozolomide.
   Google Scholar
• NEWLANDS ES, STEVENS MFG, WEDGE SR, WHEELHOUSE RT, BROCK C: Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat. Rev. (1997) 23:35–61.
   PubMed Web of Science ®Google Scholar
• ••A thorough review of pharmacology and early clinical trials.
   Google Scholar
• HVIZDOS KM, GOA KL: Temozolomide. CNS Drugs (1999) 12:237–243.
   Web of Science ®Google Scholar
• •Review of pharmacology and clinical trials.
   Google Scholar
• LIU L, MARKOWITZ S, GERSON SL: Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl) nitrosourea. Cancer Res. (1996) 56:5375–5379.
   PubMed Web of Science ®Google Scholar
• •Evaluates resistance mechanisms to temozolomide and BCNU.
   Google Scholar
• FRIEDMAN HS, JOHNSON SP, DONG Q et al.: Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Cancer Res. (1997) 57:2933–2936.
   PubMed Web of Science ®Google Scholar
• •Evaluates mismatch repair deficiency as a mechanism of resistance.
   Google Scholar
• FRIEDMAN HS, MCLENDON RE, KERBY T et al.: DNA mismatch repair and 06-alkylg-uan in e-DNA alkyltrans-ferase analysis and response to Temodal in newly diagnosed malignant glioma. J. Clin. Oncol. (1998) 16:3851–3857.
   PubMed Web of Science ®Google Scholar
• ••Correlates activity of mismatch repair and AGT to clinicalresponse.
   Google Scholar
• BAER JC, FREEMAN AA, NEWLANDS ES et al.: Depletion of 06-alkylg-uanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br. J. Cancer (1993) 67:1299–1302.
   PubMed Web of Science ®Google Scholar
• •Evaluates depletion of AGT and temozolomide cytotoxicity.
   Google Scholar
• BROCK CS, MATTHEWS JC, BROWN G et al.: Response to temozolomide in recurrent high grade gliomas is related to tumour drug concentration. Ann. Oncol (1998) 9 (Suppl. 2):174. Correlates PET uptake of 11C-temozolomide with response.
   Google Scholar
• PLOWMAN J, WAUD WR, KOUTSOUKOS AD, RUBINSTEIN LV, MOORE TD, GREVER MR: Preclinical antitumor activity of temozolomide in mice: Efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosurea. Cancer Res. (1994) 54:3793–3799.
   PubMed Web of Science ®Google Scholar
• •Demonstrates activity of temozolomide against human xenografts.
   Google Scholar
• FRIEDMAN HS, DOLAN ME, PEGG AE et al.: Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res. (19 9 5) 55:2853-2857.
   Google Scholar
• •Demonstrates activity of temozolomide against human xenografts.
   Google Scholar
• NEWLANDS ES, O'REILLY SM, GLASER MG et al.: The Charing Cross Hospital experience with temozolo-mide in patients with gliomas. Eur. J Cancer (1996) 32A:2236–2241.
   Google Scholar
• ••Results of the earliest large glioma series to receivetemozolomide.
   Google Scholar
• BOWER M, NEWLANDS ES, BLEEHEN NM et al.: Multicentre CRC Phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother. Pharmacol. (1997) 40:484–488.
   PubMed Web of Science ®Google Scholar
• •Early Phase II trial demonstrating activity of temozolomide.
   Google Scholar
• ESTLIN EJ, LASHFORD L, ABLETT S et al.: Phase I study of temozolomide in paediatric patients with advanced cancer. Br. J. Cancer (1998) 78:652–661.
   PubMed Web of Science ®Google Scholar
• •Phase I study showing activity of temozolomide in paediatric PBT.
   Google Scholar
• NICHOLSON HS, KRAILO M, AMES MM et al.: Phase Istudy of temozolomide in children and adolescents with recurrent solid tumors: A report from the Children's Cancer Group. J Clin. Oncol. (1998) 16:3037–3043.
   PubMed Web of Science ®Google Scholar
• •Phase I study showing activity of temozolomide in paediatric PBT.
   Google Scholar
• YUNG WKA, PRADOS MD, YAYA-TUR R et al.: Multicenter Phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocy-toma at first relapse. J Clin. Oncol (1999) 17:2762–2771.
   PubMed Web of Science ®Google Scholar
• ••Large Phase II trial demonstrating activity at first relapse.
   Google Scholar
• YUNG WKA, LEVIN VA, ALBRIGHT R et al.: Randomized trial of temodal (TEM) vs. procarbazine (PCB) in glioblastoma multiforme (GBM) at first relapse. Proc. ASCO (1997) 18:139a.
   Google Scholar
• •Significantly better survival for temozolomide over procarbazine.
   Google Scholar
• YUNG WKA: Temozolomide in malignant glioma. Semin. Oncol (2000) 27 (Suppl. 6):27–34.
   Google Scholar
• ••Comprehensive overview of clinical trials withtemozolomide.
   Google Scholar
• OSOBA D, BRADA M, YUNG WKA, PRADOS M: Health- related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J. Clin. Oncol. (2000) 18:1481–1491.
   PubMed Web of Science ®Google Scholar
• •Improved quality of life with temozolomide versus procarbazine.
   Google Scholar
• PRADOS MD: Future directions in the treatment of malignant gliomas with temozolomide. Semin. Oncol. (2000) 27 (Suppl. 6):41–46.
   Google Scholar
• ••Overview of combination drug studies and strategies toovercome resistance.
   Google Scholar
• SCHOLD SC, KUHN JG, CHANG SM et al.: A Phase I trial of 1,3(2-chloroethy1-1-nitrosourea plus temozolomide: A North American brain tumor consortium study. Neurooncol (2000) 2:34–39.
   Google Scholar
• •Phase I study of temozolomide and BCNU.
   Google Scholar
• BROCK CS, NEWLANDS ES, WEDGE SR et al.: Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res. (1998) 58:4363–4367.
   PubMed Web of Science ®Google Scholar
• •Phase I study of continuous, daily temozolomide over 6–7 weeks.
   Google Scholar
• FRIEDMAN HS: Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis. Semin. Oncol (2000) 27 (Suppl. 6):35–40.
   Google Scholar
• •A review of temozolomide for newly diagnosed patients and patients with neoplastic meningitis.
   Google Scholar
• YUNG WKA, JAECKLE K, KYRITSIS A, GROVES M, LEVIN V: A combination of temozolomide and interferon-A in recurrent malignant gliomas. A Phase II study. Neurooncol (1999) 1:347.
   Google Scholar
• •Improved progression-free survival with combination therapy.
   Google Scholar
• VAN DEN BENT MJ, KEIME-GUIBERT F, BRANDES AA, TAPHOORN MJB, ESKES FALM, DELATTRE JY: Temozolo-mide chemotherapy in recurrent oligodendroglioma. Neurooncol (2000) 2:S26.
   Google Scholar
• •Recurrent oligodendroglioma responds to temozolomide.
   Google Scholar
• RUTKA JT, APODACA G, STERN R, ROSENBLUM M: The extracellular matrix of the central and peripheral nervous systems: structure and function. J Neurosurg. (1988) 69:155–170.
   PubMed Web of Science ®Google Scholar
• ••A thorough review of the ECM.
   Google Scholar
• GIESE A, WESTPHAL M: Glioma invasion in the central nervous system. Neurosurg. (1996) 39:235–252.
   PubMed Web of Science ®Google Scholar
• ••A thorough review of the mechanisms of glioma invasion.
   Google Scholar
• COULDWELL WT, DE TRIBOLET N, ANTEL JP, GAUTHIER T, KUPPNER MC: Adhesion molecules and malignant gliomas: implications for tumorigenesis. j Neurosurg. (1992) 76:782–791.
   PubMed Web of Science ®Google Scholar
• ••A review of adhesion molecules and their role in glioma invasion.
   Google Scholar
• JOSEPH-SILVERSTEIN J, SILVERSTEIN RL: Cell adhesion molecules: An overview. Cancer Invest. (1998) 16:176–182.
   PubMed Web of Science ®Google Scholar
• •A general review of adhesion molecules.
   Google Scholar
• UHM JH, DOOLEY NP, VILLEMURE JG, YONG VW: Mechanisms of glioma invasion: Role matrix-metalloproteinases. Can. J Neurol. Sci. (1997) 24:3–15.
   PubMed Web of Science ®Google Scholar
• ••An extensive review of the role of MMPs in glioma invasion.
   Google Scholar
• NAKAGAWA T, KUBOTA T, KABUTO M et al.: Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors. J. Neurosurg. (1994) 81:69–77.
   PubMed Web of Science ®Google Scholar
• •Evaluates presence of MMPs and inhibitors in tumour specimens.
   Google Scholar
• VALINOIA J, HERVA R, KORPELA M, HOYHTYÄ M, TURPEENNIEMI-HUJANEN T: Matrix metalloproteinase 2 (MMP-2) immunoreactive protein is associated with poor grade and survival in brain neoplasms. J. Neurooncol. (2000) 46:81–90.
   PubMed Web of Science ®Google Scholar
• •Expression of MMP-2 correlates with high grade and poor survival.
   Google Scholar
• WOJTOWICZ-PRAGA S: Clinical potential of matrix metalloproteinase inhibitors. Drugs R & D (1999) 1:117–129.
   PubMedGoogle Scholar
• •A review of MMPIs and their clinical applications.
   Google Scholar
• YIP D, AHMAD A, KARAPETIS CS, HAWKINS CA, HARPER PG: Matrix metalloproteinase inhibitors: applications in oncology. Invest. New Drugs (1999) 17:387–399.
   PubMed Web of Science ®Google Scholar
• •A review of MMPIs and their clinical applications.
   Google Scholar
• ROTHENGERG ML, NELSON AR, HANDE KR: New drugs on the horizon: matrix metalloproteinase inhibitors. Stem Cells (1999) 17:237–240.
   PubMed Web of Science ®Google Scholar
• •A review of MMPIs and their clinical applications.
   Google Scholar
• NELSON AR, FINGLETON B, ROTHENBERG ML, MATRISIAN LM: Matrix metalloproteinases: biologic activity and clinical implications. J Clin. Oncol. (2000) 18:1135–1149.
   PubMed Web of Science ®Google Scholar
• ••A thorough review of MMPIs and their clinical applications.
   Google Scholar
• DRUMMOND AH, BECKETT P, BROWN PD et al.: Preclinical and clinical studies of MMP inhibitors in cancer. Ann. NY Acad. ScI (1999) 878:228–235.
   PubMed Web of Science ®Google Scholar
• •A review of MMPIs and their clinical applications.
   Google Scholar
• STEWARD WP: Marimastat (BB2516): Current status of development. Cancer Chemother. Pharmacol. (1999) 43:S56–S60.
   PubMed Web of Science ®Google Scholar
• ••A thorough review of clinical studies with marimastat.
   Google Scholar
• WAGNER S, STEGEN C, BOUTERFA H et al.: Expression of matrix metalloproteinases in human glioma cell lines in the presence of IL-1 O./ Neurooncol. (1998) 40:113–122.
   PubMed Web of Science ®Google Scholar
• •Expression of MMPs and inhibition of invasion by marimastat in glioma cell lines.
   Google Scholar
• TONN JC, KERKAU S, HANKE A et al.: Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro. Int. J. Cancer (1999) 80:764–772.
   PubMed Web of Science ®Google Scholar
• •Inhibition of invasion by marimastat in glioma cell lines.
   Google Scholar
• PRICE A, SHI Q, MORRIS D et al.: Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340. Clin. Cancer Res. (1999) 5:845–854.
   PubMed Web of Science ®Google Scholar
• •Inhibition of tumour growth by marimastat in a mouse model.
   Google Scholar
• WOJTOWICZ-PRAGA S, TORRI J, JOHNSON M et al.: Phase I trial of marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J. Clin. Onco/. (1998) 16:2150–2156.
   PubMed Web of Science ®Google Scholar
• •Phase I evaluation of marimastat in lung cancer patients.
   Google Scholar
• THEODOSOPOULOS PV, CHANG SM, PRADOS MD et al: Preliminary results of a Phase II study of gamma knife radiosurgery and marimastat in patients with recurrent malignant glio m as . I Neurooncol. (1999) 45:288.
   Google Scholar
• •Phase II data of marimastat after y-knife radiosurgery.
   Google Scholar
• SLICHENMYER WJ, ROWINSKY EK, DONEHOWER RC, KAUFMANN SH: The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst. (1993) 85:271–291.
   PubMed Web of Science ®Google Scholar
• ••A thorough review of camptothecin derivatives in oncology.
   Google Scholar
• KUHN JG: Pharmacology of irinotecan. Oncology (1998) 12:39–42.
   PubMed Web of Science ®Google Scholar
• •A review of the pharmacology of irinotecan.
   Google Scholar
• HARE CB, ELION GB, HOUGHTON PJ et al.: Therapeutic efficacy of the topoisomerase I inhibitor 7-ethy1-10-(441 -piperidino]-1 -pip eridino)-carbonylox y-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother. Pharmacol. (1997) 39:187–191.
   PubMed Web of Science ®Google Scholar
• •Irinotecan demonstrates significant activity against PBT xenografts.
   Google Scholar
• COGGINS CA, ELION GB, HOUGHTON PJ et al.: Enhance- ment of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. Cancer Chemother. Pharmacol. (1998) 41:485–490.
   PubMed Web of Science ®Google Scholar
• •Irinotecan activity augmented by alkylating agents.
   Google Scholar
• FRIEDMAN HS, CASTELLINO RC, ELION GB et al.: Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts. Cancer Chemother. Pharmacol. (2000) 45:345–349.
   PubMed Web of Science ®Google Scholar
• •Enhanced activity of irinotecan plus BCNU is schedule-dependent.
   Google Scholar
• CHEN T, HE S, WEISS MH: CPT-11 induces apoptosis in meningioma cells. J. Neurooncol. (1999) 45:274.
   Google Scholar
• •Irinotecan has activity against meningioma cells by inducing apoptosis.
   Google Scholar
• DE FORNI M, BUGAT R, CHABOT GG et al.: Phase I and pharmacokinetic study of the camptothecin derivative irintocan, administered on a weekly schedule in cancer patients. Cancer Res. (1994) 54:4347–4354.
   PubMed Web of Science ®Google Scholar
• •Phase I evaluation of irinotecan in solid tumour patients.
   Google Scholar
• ROTHENBERG ML, KUHN JG, BURRIS HA et al.: Phase I and pharmacokinetic trial of weekly CPT-11. I Clin. Oncol. (1993) 11:2194–2204.
   PubMed Web of Science ®Google Scholar
• •Phase I evaluation of irinotecan in solid tumour patients.
   Google Scholar
• HECHT JR: Gastrointestinal toxicity of irinotecan. Oncology (1998) 12:72–78.
   PubMed Web of Science ®Google Scholar
• •A detailed description of the diarrhoea syndrome of irinotecan.
   Google Scholar
• FRIEDMAN HS, PETROS WP, FRIEDMAN AH et al.:Irinote- can therapy in adults with recurrent or progressive malignant glioma. I Clin. Oncol (1999) 17:1516–1525.
   PubMed Web of Science ®Google Scholar
• ••Evaluation of 60 patients with malignant glioma treated withirinotecan.
   Google Scholar
• GILBERT MR, GROSSMAN SA, MIKKELSON T, SUPKO J, PRIET R, PIANTADOSI S: The impact of anticonvulsants on CPT-11 dose in patients with recurrent malignant glioma. Neurooncol. (1999) 1:313.
   Google Scholar
• •Abstract of preliminary data from Phase I study of irinotecan and the effect of anticonvulsants.
   Google Scholar
• FOLKMAN J: Clinical applications of research on angiogenesis. N Engl. J. Med. (1995) 333:1757–1763.
   PubMed Web of Science ®Google Scholar
• ••A seminal review of angiogenesis and applications tooncology.
   Google Scholar
• PLATE KH: Mechanisms of angiogenesis in the brain. J. Neuropath. Exp. Neurol. (1999) 58:313–320.
   PubMed Web of Science ®Google Scholar
• ••A thorough review of normal and neoplastic angiogenesis inthe brain.
   Google Scholar
• WESSELING P, RUITER DJ, BURGER PC: Angiogenesis in brain tumors; pathobiological and clinical aspects. J. Neurooncol. (1997) 32:253–265.
   PubMed Web of Science ®Google Scholar
• ••A thorough review of angiogenesis in PBT.
   Google Scholar
• VEIKKOLA T, KARKKAINEN M, CLAESSON-WELSH L, ALITALO K: Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. (2000) 60:203–212.
   PubMed Web of Science ®Google Scholar
• •A review of VEGF, VEGF receptors and control of angiogenesis.
   Google Scholar
• PIETSCH T, VALTER MM, WOLF HK, VON DEIMLING A et al.: Expression and distribution of vascular endothe-lial growth factor protein in human brain tumors. Acta Neuropathol. (1997) 93:109–117.
   Google Scholar
• •Expression and distribution of VEGF and VEGF receptors in PBTs.
   Google Scholar
• BERNSEN HJJA, VAN DER KOGEL AJ: Antiangiogenic therapy in brain tumor models. J. Neurooncol. (1999) 45:247–255.
   PubMed Web of Science ®Google Scholar
• ••A thorough review of anti-angiogenic treatment and PBTmodels.
   Google Scholar
• KIRSCH M, STRASSER J, ALLENDE R, BELLO L, ZHANG J, BLACK PM: Angiostatin suppresses malignant glioma growth in vivo. Cancer Res. (1998) 58:4654–4659.
   PubMed Web of Science ®Google Scholar
• •Angiostatin inhibited growth and vascularity in glioma xenografts.
   Google Scholar
• BERNSEN HJJA, RIJKEN PFJW, PETERS H, BAKKER H, VAN DER KOGEL AJ: The effect of the anti-angiogenic agent TNP-470 on tumor growth and vascularity in low passaged xenografts of human gliomas in nude mice. J. Neurooncol. (1998) 38:51–57.
   PubMed Web of Science ®Google Scholar
• •Inconsistent results of TNP-470 against glioma xenografts.
   Google Scholar
• BERNSEN HJJA, RIJKEN PFJW, PETERS JPW et al.: Suramin treatment of human glioma xenografts; effects on tumor vasculature and oxygenation status. J. Neurooncol. (1999) 44:129–136.
   PubMed Web of Science ®Google Scholar
• •Suramin inhibited growth of glioma xenografts.
   Google Scholar
• LAIRD AD, VAJKOCZY P, SHAWVER LK et al.: SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res. (2000) 60:4152–4160.
   PubMed Web of Science ®Google Scholar
• •5U6668 inhibits angiogenesis and growth of solid tumour xenografts, including glioma.
   Google Scholar
• DREVS J, DROLL A, MROSS K, UNGER C: Angiogenesis inhibition: drugs in clinical trials. Onkologie (1999) 22:282–290.
   Web of Science ®Google Scholar
• ••A thorough review of angiogenesis inhibitors in clinicaltrials.
   Google Scholar
• FINE HA, FIGG WD, JAECKLE K et al: A Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. I Clin. Oncol. (2000) 18:708–715.
   PubMed Web of Science ®Google Scholar
• •Thalidomide demonstrated modest activity against recurrent gliomas.
   Google Scholar
• SHORT S, TRAISH D, DOWE A, HINES F, BRADA M: Thalidomide as an antiangiogenic agent in relapsed gliomas. Neurooncol. (2000) 2:S53.
   Google Scholar
• •Thalidomide demonstrated modest activity against recurrent gliomas.
   Google Scholar
• GRUBER ML, GLASS J: Phase I/II study of carboplatin and thalidomide in recurrent glioblastoma multiforme. Cancer Invest. (2000) 18:41–42.
   Google Scholar
• •Thalidomide and carboplatin demonstrated activity against recurrent gliomas.
   Google Scholar
• GROSSMAN SA, BREM S, LESSER G et al.: Efficacy, toxicity and pharmacology of suramin in adults with recurrent high grade astrocytomas. Neurooncol. (1999) 1:314.
   Google Scholar
• •Initial trial of suramin for patients with recurrent astrocytomas.
   Google Scholar
• ROWINSKY EK, DONEHOWER RC: Paclitaxel (TaxolTI. N Engl. J. Med. (1995) 332:1004–1014.
   PubMed Web of Science ®Google Scholar
• ••A thorough review of pharmacology and antitumour activityof paclitaxel.
   Google Scholar
• WANG TH, WANG HS, SOONG YK: Paclitaxel-induced cell death. Where the cell cycle and apoptosis come together. Cancer (2000) 88:2619–2628.
   Google Scholar
• ••A detailed review of the mechanism of paclitaxel-inducedapoptosis.
   Google Scholar
• TERZIS AJA, THORSEN F, HEESE 0 et al: Proliferation, migration and invasion of human glioma cells exposed to paclitaxel (Taxol) in vitro. Br. J. Cancer (1997) 75:1744–1752.
   PubMed Web of Science ®Google Scholar
• •Paclitaxel inhibits glioma cell proliferation, migration and invasion.
   Google Scholar
• GUPTA N, HU LJ, DEEN DF: Cytotoxicity and cell-cycle effects of paclitaxel when used as a single agent and in combination with ionizing radiation. Int. J. Rad. Oncol Biol. Phys. (1997) 37:885–895.
   PubMed Web of Science ®Google Scholar
• •Paclitaxel-sensitised glioma cells to cytoxicity of irradiation.
   Google Scholar
• GLANTZ MJ, CHAMBERLAIN MC, CHANG SM, PRADOS MD, COLE BF: The role of paclitaxel in the treatment of primary and metastatic brain tumors. Sem. Rad. Oncol (1999) 9:27–33.
   PubMed Web of Science ®Google Scholar
• ••A thorough review of clinical trials using paclitaxel for PBTand MBT.
   Google Scholar
• GLANTZ MJ, CHOY H, KEARNS CM et al.: Paclitaxel distri- bution in plasma and central nervous systems of humans and rats with brain tumors. J. Natl. Cancer Inst. (1995) 87:1077–1081.
   PubMed Web of Science ®Google Scholar
• •Paclitaxel has poor penetration of the blood-brain and blood-tumour barriers.
   Google Scholar
• PRADOS MD, SCHOLD SC, SPENCE AM et al: Phase II study of paclitaxel in patients with recurrent malignant glioma. J Clin. Oncol. (1996) 14:2316–2321.
   PubMed Web of Science ®Google Scholar
• •Paclitaxel demonstrated modest efficacy against recurrent glioma.
   Google Scholar
• CHANG SM, KUHN JG, RIZZO J et al.: Phase I study of paclitaxel in patients with recurrent malignant glioma: A North American Brain Tumor Consortium report. J. Clin. Oncol (1998) 16:2188–2194.
   PubMed Web of Science ®Google Scholar
• ••Important Phase I study demonstrating effect of anticonvul-sants on dosing of paclitaxel.
   Google Scholar
• CHAMBERLAIN MC, KORMANIK PA: Salvage chemotherapy with paclitaxel for recurrent oligoden-drogliomas. I Clin. Oncol (1997) 15:3427–3432.
   PubMed Web of Science ®Google Scholar
• •Paclitaxel demonstrated activity against recurrent oligodendroglioma.
   Google Scholar
• CHAMBERLAIN MC, KORMANIK PA: Salvage chemotherapy with Taxol for recurrent anaplastic astrocytomas. I Neurooncol. (1997) 15:3427–3432.
   Google Scholar
• •Paclitaxel demonstrated activity against recurrent AA.
   Google Scholar
• BOYD TS, MEHTA MP: Stereotactic radiosurgery for brain metastases.
   Google Scholar
• ••Oncology (1999) 13:1397-1409. A thorough review of radiosurgical treatment of MBT.
   Google Scholar
• ABREY LE, OLSON JD, BOUTROS DY et al.: A Phase II study of temozolomide for recurrent brain metastases. Proc. ASCO (2000) 19:166a.
   Google Scholar
• ••Temozolomide has modest activity against recurrent MBT.
   Google Scholar
• FRANCIOSI V, COCCONI G, MICHIARA M et al.: Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, non-small cell lung carcinoma, or malignant melanoma. A prospective study. Cancer (1999) 85:1599–1605.
   Google Scholar
• ••Iv. cisplatin and etoposide is very active against MBT fromlung and breast.
   Google Scholar
• GELMAN M, CHAKERES DW, NEWTON HB: Brain tumors: Complications of cerebral angiography accompanied by intra-arterial chemotherapy. Radio]. (1999) 213:135–140.
   Google Scholar
• ••Ia. chemotherapy is active against PBT and MBT, with a lowcomplication rate.
   Google Scholar
• NEWTON HB, SNYDER MA, STEVENS C et al: Intra-arterial carboplatin and intravenous etoposide for the treatment of metastatic brain tumors. Ann. Oncol. (2000) 11:131–132.
   Web of Science ®Google Scholar
• ••Ia. chemotherapy very active against MBT.
   Google Scholar
• DOOLITTLE ND, MINER ME, HALL WA et al: Safety and efficacy of a multicenter study using intra-arterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer (2000) 88:637–647.
   PubMed Web of Science ®Google Scholar
• ••Ia. chemotherapy with blood-brain barrier disruption hasactivity against PBT and MBT.
   Google Scholar
• SHAPIRO JR, COONS SW: Genetics of adult malignant gliomas. BNI Quarterly (1998) 14:27–42.
   Google Scholar
• ••A thorough review.
   Google Scholar
• SCHECK AC: Molecular biology of chemotherapy and resistance. BNI Quarterly (1998) 14:43–54.
   Google Scholar
• ••A thorough review.
   Google Scholar
• NEWTON HB: Role of the MMAC1/PTEN gene in the transformation and behavior of gliomas. Neurol Network Comm. (1999) 3:290–298.
   Google Scholar
• •Review and commentary of the MMACUPTEN gene and molecular neuro-oncology.
   Google Scholar
• CAIRNCROSS JG, UEKI K, ZLATESCU MC et al.: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendro-gliomas. j Nati Cancer Inst. (1998) 90:14731479.
   Google Scholar
• •Seminal paper demonstrating genetic abnormalities predic-tive of chemosensitivity in anaplastic oligodendrogliomas.
   Google Scholar
• SMITH JS, PERRY A, BORELL TJ et al.: Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas and mixed oligoastrocytomas. J. Clin. Oncof (2000) 18:636–645.
   PubMed Web of Science ®Google Scholar
• ••Detailed study finds loss of lp and 19q predictive in allgrades of oligo, but not astrocytomas or mixed oligoastrocytomas.
   Google Scholar